JP2022535735A5 - - Google Patents
Info
- Publication number
- JP2022535735A5 JP2022535735A5 JP2021570299A JP2021570299A JP2022535735A5 JP 2022535735 A5 JP2022535735 A5 JP 2022535735A5 JP 2021570299 A JP2021570299 A JP 2021570299A JP 2021570299 A JP2021570299 A JP 2021570299A JP 2022535735 A5 JP2022535735 A5 JP 2022535735A5
- Authority
- JP
- Japan
- Prior art keywords
- aso
- cpsgps
- cps
- sequence
- lngpslnapslntpslnapslnapsapsaps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855793P | 2019-05-31 | 2019-05-31 | |
| US62/855,793 | 2019-05-31 | ||
| US201962937760P | 2019-11-19 | 2019-11-19 | |
| US62/937,760 | 2019-11-19 | ||
| US201962943532P | 2019-12-04 | 2019-12-04 | |
| US62/943,532 | 2019-12-04 | ||
| PCT/US2020/035212 WO2020243490A2 (en) | 2019-05-31 | 2020-05-29 | Modified gapmer oligonucleotides and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535735A JP2022535735A (ja) | 2022-08-10 |
| JP2022535735A5 true JP2022535735A5 (cg-RX-API-DMAC7.html) | 2023-05-31 |
Family
ID=72179172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570299A Pending JP2022535735A (ja) | 2019-05-31 | 2020-05-29 | 修飾ギャップマーオリゴヌクレオチドおよび使用方法 |
Country Status (15)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021119325A1 (en) * | 2019-12-12 | 2021-06-17 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| CA3187388A1 (en) * | 2020-07-27 | 2022-02-03 | Jin Hong | Hbv binding oligonucleotides and methods of use |
| CN117500924A (zh) * | 2020-12-31 | 2024-02-02 | 赛卡纳制药股份两合公司 | 用于降低血管紧张素转换酶2(ace2)表达的寡核苷酸及其在治疗病毒感染中的用途 |
| US20250243491A1 (en) | 2021-09-01 | 2025-07-31 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| CA3230382A1 (en) | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| KR20240131441A (ko) | 2022-01-10 | 2024-08-30 | 오스퍼바이오 테라퓨틱스 인크. | B형 간염 바이러스(hbv) 발현의 조절 |
| JP2025509552A (ja) * | 2022-03-17 | 2025-04-11 | アリゴス セラピューティクス,インコーポレーテッド | 修飾ギャップマーオリゴマー及びその使用方法 |
| WO2024182446A2 (en) | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| US20240352464A1 (en) | 2023-03-07 | 2024-10-24 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| EP4600358A4 (en) * | 2023-04-14 | 2026-05-20 | Rigerna Therapeutics Suzhou Co Ltd | COMPOUND TO INHIBIT C3 GENE EXPRESSION, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USES |
| US20250368996A1 (en) | 2024-05-14 | 2025-12-04 | Aligos Therapeutics, Inc. | Modified antisense oligonucleotides for treating hepatitis b virus |
| CN120796266A (zh) * | 2024-07-08 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 一种降低hbv基因表达的反义寡核苷酸及其应用 |
| WO2026124677A1 (zh) * | 2024-12-13 | 2026-06-18 | 成都先衍生物技术有限公司 | 一种4'-螺环修饰的苏糖核苷亚磷酰胺化合物及其在寡核苷酸中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5985662A (en) * | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| WO2005009346A2 (en) | 2003-06-24 | 2005-02-03 | Mirus Corporation | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| ES2651308T3 (es) * | 2009-10-16 | 2018-01-25 | Glaxo Group Limited | Inhibidores antisentido de HBV |
| AU2010312751B2 (en) | 2009-10-29 | 2014-07-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
| US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| CN104684857B (zh) | 2012-09-11 | 2018-10-12 | 3M创新有限公司 | 具有分区的结构的玻璃粒料 |
| EP2899197B1 (en) | 2012-09-21 | 2017-03-22 | Osaka University | Oligonucleotide and artificial nucleoside having guanidine bridge |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| EP3109254B1 (en) | 2014-02-18 | 2018-04-11 | Osaka University | Crosslinked nucleoside and nucleotide |
| GB201408623D0 (en) * | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| AU2015329974B2 (en) | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
| EP3221329A1 (en) | 2014-11-19 | 2017-09-27 | Roche Innovation Center Copenhagen A/S | Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages |
| EP3353305A4 (en) | 2015-09-25 | 2019-09-18 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| AU2017285350A1 (en) * | 2016-06-17 | 2018-12-20 | F. Hoffmann-La Roche Ag | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection |
| US11286275B2 (en) | 2017-02-21 | 2022-03-29 | Osaka University | Nucleic acid compound and oligonucleotide |
| US11261440B2 (en) | 2017-02-21 | 2022-03-01 | Osaka University | Antisense oligonucleic acid |
| KR20200030594A (ko) * | 2017-10-16 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자 |
| US20200147124A1 (en) | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| KR20210126636A (ko) | 2019-02-14 | 2021-10-20 | 알리고스 테라퓨틱스 인코포레이티드 | 이환식 설폰아마이드 |
-
2020
- 2020-05-29 KR KR1020217042828A patent/KR20220024192A/ko not_active Withdrawn
- 2020-05-29 TW TW109118218A patent/TW202113079A/zh unknown
- 2020-05-29 SG SG11202112741XA patent/SG11202112741XA/en unknown
- 2020-05-29 EP EP20760617.9A patent/EP3976056A2/en not_active Withdrawn
- 2020-05-29 PE PE2021001964A patent/PE20220574A1/es unknown
- 2020-05-29 MX MX2021014206A patent/MX2021014206A/es unknown
- 2020-05-29 AU AU2020282828A patent/AU2020282828A1/en not_active Abandoned
- 2020-05-29 CA CA3141874A patent/CA3141874A1/en active Pending
- 2020-05-29 BR BR112021023488A patent/BR112021023488A2/pt not_active Application Discontinuation
- 2020-05-29 US US16/887,063 patent/US11466274B2/en active Active
- 2020-05-29 WO PCT/US2020/035212 patent/WO2020243490A2/en not_active Ceased
- 2020-05-29 JP JP2021570299A patent/JP2022535735A/ja active Pending
- 2020-05-29 CN CN202080039766.4A patent/CN113905744A/zh active Pending
-
2021
- 2021-11-21 IL IL288259A patent/IL288259A/en unknown
- 2021-12-29 CO CONC2021/0018034A patent/CO2021018034A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2242291T3 (es) | Nucleotidos bi y triciclicos, analogos de nucleotidos y oligonucleotidos. | |
| KR102500675B1 (ko) | B형 간염 바이러스 감염에 대한 RNAi 작용제 | |
| EP2334692B1 (en) | Rna monomers containing o-acetal levulinyl ester groups and their use in rna microarrays | |
| JP2022551124A5 (cg-RX-API-DMAC7.html) | ||
| JP2023515664A5 (cg-RX-API-DMAC7.html) | ||
| JP4791043B2 (ja) | 同一固体支持体上で、2以上のオリゴヌクレオチドをタンデムに合成するための方法および組成物 | |
| PE20220574A1 (es) | Oligonucleotidos gapmer modificados y metodos de uso | |
| JP2005533517A5 (cg-RX-API-DMAC7.html) | ||
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| HUT76094A (en) | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties | |
| US7034133B2 (en) | Oligonucleotide analogues | |
| KR102533038B1 (ko) | 변형된 올리고뉴클레오티드 및 사용 방법 | |
| JP2021523720A5 (cg-RX-API-DMAC7.html) | ||
| CN101784556A (zh) | 用于rna合成的硫代碳保护基团 | |
| EP1007655A1 (en) | Rnase l activators and antisense oligonucleotides effective to treat rsv infections | |
| JPH09511250A (ja) | 核酸治療に有用な修飾オリゴヌクレオチド及び中間体 | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JP2021505129A5 (cg-RX-API-DMAC7.html) | ||
| JP2019529406A5 (cg-RX-API-DMAC7.html) | ||
| RU2020135289A (ru) | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в | |
| Adah et al. | Chemistry and biochemistry of 2', 5'-oligoadenylate-based antisense strategy | |
| JP2024073525A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521491A5 (cg-RX-API-DMAC7.html) | ||
| WO1996003500A1 (en) | Sustance with antiviral activity | |
| JP2025509552A5 (cg-RX-API-DMAC7.html) |